PMID- 31882550
OWN - NLM
STAT- MEDLINE
DCOM- 20200602
LR  - 20200602
IS  - 1790-6245 (Electronic)
IS  - 1109-6535 (Print)
IS  - 1109-6535 (Linking)
VI  - 17
IP  - 1
DP  - 2020 Jan-Feb
TI  - Chromosome Translocation t(14;21)(q11;q22) Activates Both OLIG1 and OLIG2 in 
      Pediatric T-cell Lymphoblastic Malignancies and May Signify Adverse Prognosis.
PG  - 41-48
LID - 10.21873/cgp.20166 [doi]
AB  - BACKGROUND/AIM: The chromosome translocation t(14;21)(q11;q22) was reported in 
      four pediatric T-cell lymphoblastic leukemias and was shown to activate the OLIG2 
      gene. MATERIALS AND METHODS: A pediatric T-cell lymphoblastic lymphoma was 
      investigated using G-banding chromosome analysis, fluorescence in situ 
      hybridization (FISH), and immunocytochemistry. RESULTS: The malignant cells 
      carried a t(14;21)(q11;q22) aberration. The translocation moves the enhancer 
      elements of TRA/TRD from band 14q11 to 21q22, a few thousands kbp downstream of 
      OLIG1 and OLIG2, resulting in the production of both OLIG1 and OLIG2 proteins. 
      CONCLUSION: The translocation t(14;21)(q11;q22) occurs in some pediatric T-cell 
      lymphoblastic malignancies. Activation of both OLIG1 and OLIG2 by 
      t(14;21)(q11;q22) in T-lymphoblasts and the ensuing deregulation of thousands of 
      genes could explain the highly malignant disease and resistance to treatment that 
      has characterized this small group of patients.
CI  - Copyright(c) 2020, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Panagopoulos, Ioannis
AU  - Panagopoulos I
AD  - Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, 
      The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway 
      ioannis.panagopoulos@rr-research.no.
FAU - Gorunova, Ludmila
AU  - Gorunova L
AD  - Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, 
      The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
FAU - Johannsdottir, Inga Maria Rinvoll
AU  - Johannsdottir IMR
AD  - Department of Pediatric Cancer and Blood Disorders, Oslo University Hospital, 
      Oslo, Norway.
AD  - National Advisory Unit on Late Effects after Cancer Treatment, Oslo University 
      Hospital, Oslo, Norway.
FAU - Andersen, Kristin
AU  - Andersen K
AD  - Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, 
      The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
FAU - Holth, Arild
AU  - Holth A
AD  - Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, 
      Oslo, Norway.
FAU - Beiske, Klaus
AU  - Beiske K
AD  - Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, 
      Oslo, Norway.
AD  - Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, 
      Norway.
FAU - Heim, Sverre
AU  - Heim S
AD  - Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, 
      The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
AD  - Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, 
      Norway.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Greece
TA  - Cancer Genomics Proteomics
JT  - Cancer genomics & proteomics
JID - 101188791
RN  - 0 (Basic Helix-Loop-Helix Transcription Factors)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (OLIG1 protein, human)
RN  - 0 (OLIG2 protein, human)
RN  - 0 (Oligodendrocyte Transcription Factor 2)
SB  - IM
MH  - Adolescent
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Basic Helix-Loop-Helix Transcription Factors/*genetics
MH  - Chromosome Banding
MH  - Chromosomes, Human, Pair 14/*genetics
MH  - Chromosomes, Human, Pair 21/*genetics
MH  - Fatal Outcome
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Nerve Tissue Proteins/*genetics
MH  - Oligodendrocyte Transcription Factor 2/*genetics
MH  - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/genetics/*pathology
MH  - Prognosis
MH  - *Translocation, Genetic
PMC - PMC6937122
OTO - NOTNLM
OT  - OLIG1 expression
OT  - OLIG2 expression
OT  - Pediatric T-cell lymphoblastic lymphoma
OT  - TRA/TRD enhancer
OT  - chromosome translocation t(14;21)(q11;q22)
OT  - unfavorable prognosis
COIS- The Authors declare that they have no potential conflicts of interest.
EDAT- 2019/12/29 06:00
MHDA- 2020/06/03 06:00
PMCR- 2020/01/03
CRDT- 2019/12/29 06:00
PHST- 2019/10/27 00:00 [received]
PHST- 2019/11/11 00:00 [revised]
PHST- 2019/11/15 00:00 [accepted]
PHST- 2019/12/29 06:00 [entrez]
PHST- 2019/12/29 06:00 [pubmed]
PHST- 2020/06/03 06:00 [medline]
PHST- 2020/01/03 00:00 [pmc-release]
AID - 17/1/41 [pii]
AID - 10.21873/cgp.20166 [doi]
PST - ppublish
SO  - Cancer Genomics Proteomics. 2020 Jan-Feb;17(1):41-48. doi: 10.21873/cgp.20166.